Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145751 | 0.98 | PSEN1 (0.44) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8895660 | 0.86 | ALDH1A1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4313039 | 0.84 | ALDH1A1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4313036 | 0.84 | ALDH1A1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7359870 | 0.81 | HPGD (0.43) | CTSDEPHX1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL7359864 | 0.81 | HPGD (0.43) | CTSDEPHX1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4136042 | 0.78 | CTSK (0.54) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL4141669 | 0.78 | TSHR (0.51) | HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL7882899 | 0.77 | KMT2A (0.53) | CTSDEPHX1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4144410 | 0.77 | CTSK (0.55) | CNR2BCHECNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CNR2 57/4885PSEN1 2734/4885PSEN2 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.